D L Bartlett

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Gallbladder cancer
    D L Bartlett
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Semin Surg Oncol 19:145-55. 2000
  2. ncbi Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer
    D L Bartlett
    Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 129:176-87. 2001
  3. ncbi Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome
    H R Alexander
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 124:1160-6. 1998
  4. ncbi Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
    H R Alexander
    Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Clin Oncol 16:1479-89. 1998
  5. ncbi Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion
    T E Lans
    Surgery Branch, Division of Clinical Sciences and the Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:784-90. 2001
  6. ncbi Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms
    H R Alexander
    Surgical Metabolism Section, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 4:2357-62. 1998
  7. ncbi Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome
    A C Berger
    Surgery Branch and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:3051-7. 2001
  8. ncbi A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer
    M A Steller
    Section of Gynecologic Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 43:106-14. 1999
  9. ncbi A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases
    A L Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Surg Oncol 8:741-5. 2001
  10. ncbi A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen le
    S K Libutti
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1502, USA
    Ann Surg Oncol 8:779-86. 2001

Collaborators

Detail Information

Publications13

  1. ncbi Gallbladder cancer
    D L Bartlett
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Semin Surg Oncol 19:145-55. 2000
    ..This review will discuss the epidemiology, pathology, and staging of gallbladder cancer and describe the appropriate surgical management based on the stage of the cancer...
  2. ncbi Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer
    D L Bartlett
    Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 129:176-87. 2001
    ..HAI appears to prolong the duration of response after IHP, and this combined treatment strategy deserves additional clinical evaluation as a therapeutic modality in this setting...
  3. ncbi Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome
    H R Alexander
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 124:1160-6. 1998
    ..The purpose of this analysis was to identify perioperative factors associated with long-term (> or = 5 years) biochemical cures...
  4. ncbi Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver
    H R Alexander
    Surgical Metabolism Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Clin Oncol 16:1479-89. 1998
    ....
  5. ncbi Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion
    T E Lans
    Surgery Branch, Division of Clinical Sciences and the Biostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 7:784-90. 2001
    ..However, these measurable differences were transient and did not appear to be of major clinical consequence. Prior to its routine use, the benefit of TNF in isolation perfusion should be demonstrated in random assignment trials...
  6. ncbi Augmented capillary leak during isolated hepatic perfusion (IHP) occurs via tumor necrosis factor-independent mechanisms
    H R Alexander
    Surgical Metabolism Section, Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 4:2357-62. 1998
    ..These data indicate that TNF must continue to be critically evaluated in clinical trials before it is routinely used with melphalan in isolated organ perfusion...
  7. ncbi Prognostic value of initial fasting serum gastrin levels in patients with Zollinger-Ellison syndrome
    A C Berger
    Surgery Branch and Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 19:3051-7. 2001
    ..The level of FSG at presentation may be useful in planning the nature and extent of the initial evaluation and management in patients with sporadic ZES...
  8. ncbi A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer
    M A Steller
    Section of Gynecologic Oncology, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 43:106-14. 1999
    ..Patients and..
  9. ncbi A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases
    A L Feldman
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Ann Surg Oncol 8:741-5. 2001
    ..Elevated endostatin levels during follow-up are associated with disease progression. Understanding the role of endogenous endostatin in cancer patients may lead to novel strategies to inhibit tumor angiogenesis...
  10. ncbi A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen le
    S K Libutti
    Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892 1502, USA
    Ann Surg Oncol 8:779-86. 2001
    ..We evaluated 2-[18F] fluoro-2-deoxy-D-glucose and positron emission tomography (FDG-PET) scan and CEA scan before second-look laparotomy as a means of localizing recurrent colorectal cancer...
  11. ncbi Yaba-like disease virus: an alternative replicating poxvirus vector for cancer gene therapy
    Y Hu
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:10300-8. 2001
    ..YLD virus has favorable characteristics as a vector for cancer gene therapy, and this potential should be explored further...
  12. ncbi Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma
    T G Zogakis
    Surgery Branch and the Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Ann Surg Oncol 8:771-8. 2001
    ..In addition, patients who have a CR after ILP and have a history of prior treatment or larger lesions should be considered for adjuvant systemic therapy...
  13. ncbi Reoperation for hyperparathyroidism in multiple endocrine neoplasia type 1
    M H Kivlen
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Surgery 130:991-8. 2001
    ..The total number of glands accounted for after reoperation is not associated with successful outcome...